by From Dean Baker It seems more than a bit bizarre, but in a discussion of alternative to patents for financing the development of new drugs and vaccines, publicly funded open-source research is not mentioned. This is peculiar since so much of the research into treatments and vaccines for the coronavirus are in effect being open-sourced, with researchers posting results as soon as they are available. Advance, open-sourced funding would mean that any new drugs or vaccines that are developed could be sold as cheap generics from the first day they are available. It is also bizarre that economists have such a hard time envisioning open source research, since all of our research is essentially open source. Economists are paid by universities and think tanks. Extraordinary work can qualify
Topics:
Dean Baker considers the following as important: Uncategorized
This could be interesting, too:
Editor writes In search of radical alternatives
Stavros Mavroudeas writes «Οι καταστροφικές επιπτώσεις της ΕΕ στην Ελλάδα και τους εργαζόμενους» – Στ.Μαυρουδέας ΠΡΙΝ 20-21/4/2024
Stavros Mavroudeas writes «Κοινωνικές επιστήμες: είδος υπό εξαφάνιση;» – εκδήλωση Παντειέρα-Attac, 23/4/2024, 5.30μμ Πάντειο
Lars Pålsson Syll writes Cutting-edge macroeconomics …
from Dean Baker
It seems more than a bit bizarre, but in a discussion of alternative to patents for financing the development of new drugs and vaccines, publicly funded open-source research is not mentioned. This is peculiar since so much of the research into treatments and vaccines for the coronavirus are in effect being open-sourced, with researchers posting results as soon as they are available. Advance, open-sourced funding would mean that any new drugs or vaccines that are developed could be sold as cheap generics from the first day they are available.
It is also bizarre that economists have such a hard time envisioning open source research, since all of our research is essentially open source. Economists are paid by universities and think tanks. Extraordinary work can qualify for a Nobel Prize, which is a big chunk of money, but the vast majority of economists get the bulk of their income from ongoing funding streams, where they are expected to produce research that will be widely available.
Perhaps economists believe that this route has not been effective in supporting good research in economics. This could explain their reluctance to envision open source research in biomedical innovation and elsewhere.